A next-generation precision oncology company leading the way in bringing expression-based therapies into the precision era with predictive treatment selection algorithms. We combine DNA and quantitative RNA profiling on a single small tumor tissue sample to expand precision treatment selection to immunotherapy, antibody-drug conjugates and angiogenesis inhibitors. Expanded treatment selection that goes beyond DNA has the potential to double the clinical actionability of molecular profiling and improve outcomes for more patients than ever before.